Common misconceptions about solid-phase peptide synthesis

Solid-phase peptide synthesis (SPPS) is a laboratory method in which a peptide chain is assembled stepwise while anchored to an insoluble polymeric support, with reagents and by-products removed by filtration and washing between steps. The technique is also referred to by the name of a specific variant, silica-assisted solid-phase peptide synthesis (SiPPS), when a non-swelling silica-based resin is used in place of a conventional swelling polymer [3]. SPPS is a preparative chemistry method rather than a compound: it has no sequence, formula or molecular weight of its own. The products it generates do, and the evidence summarised here concerns defined peptides, including the human cathelicidin LL-37 (37 residues; net charge +6) [1].

The work described below centres on peptide backbone chemistry and its downstream effects on proteolytic susceptibility and on host-defence peptide signalling, including the immunomodulatory activity associated with the cathelicidin family [1].

Research Studies

SPPS and the misconception that resin swelling is required for coupling

A persistent assumption is that efficient chain assembly depends on a resin that swells in the reaction solvent. A non-swelling silica-based resin was used for peptide synthesis in a strategy similar to conventional SPPS, referred to as silica-assisted solid-phase peptide synthesis (SiPPS) [3]. In that work, a 2-h coupling appeared to favour coupling relative to a 1-h standard coupling [3]. The finding is a methodological observation from a synthesis study, not a claim about biological activity.

SPPS and the misconception that coupling time is a fixed parameter

Coupling time is often treated as a constant across protocols. The SiPPS work compared a 1-h standard coupling with a 2-h coupling and reported that the longer interval seemed to favour coupling [3]. This is a comparison of two reaction conditions within one synthetic strategy, and it does not establish an optimum for other resins, sequences or scales.

LL-37 and the misconception that antimicrobial peptides cannot be stabilised

LL-37 couples broad-spectrum antimicrobial activity with immunomodulatory function, but rapid proteolysis and peptidylarginine deiminase (PAD)-mediated citrullination limit its therapeutic use [1]. Building blocks of 2,3-diaminopropionic acid functionalised with an oxa-acid spacer were used to shift the functional profile of LL-37, with reported enhancement of enzymatic stability and selective suppression of neutrophil degranulation [1]. These are in vitro and biochemical findings on a modified peptide; they are not evidence of clinical effect.

LL-37 and the misconception that backbone modification abolishes function

Modification of a peptide backbone is sometimes assumed to destroy its activity. In the LL-37 work, incorporation of 2,3-diaminopropionic acid building blocks bearing an oxa-acid spacer was associated with a shifted functional profile rather than simple loss of function, alongside enhanced enzymatic stability and selective suppression of neutrophil degranulation [1]. The observations were made in laboratory systems, and the selectivity reported there should not be generalised to other cell types or to whole organisms.

D-amino acids and the misconception that non-natural residues are unusable

D-amino acids, the non-natural enantiomers of L-amino acids, have been described as tools in peptide drug development because of their resistance to proteolytic degradation, enhanced conformational rigidity and reduced immunogenicity [2]. A historical and developmental review of FDA-approved drugs containing D-amino acids documents that such residues are compatible with approved products [2]. This is a review-level observation about drug development history; it does not indicate that any particular D-amino acid substitution will improve a given peptide.

SPPS and the misconception that synthesis route predicts stability

The route by which a peptide is assembled does not by itself determine how that peptide behaves in biological systems. The SiPPS study addressed coupling behaviour on a non-swelling silica resin [3], whereas the LL-37 study addressed enzymatic stability and neutrophil degranulation after specific backbone modification [1]. These are separate questions measured in separate systems, and results from one do not transfer to the other.

Peptide stability and the misconception that proteolysis resistance equals efficacy

Resistance to proteolytic degradation is a biochemical property. In the LL-37 work it was reported alongside selective suppression of neutrophil degranulation in laboratory assays [1], and in the D-amino acid review it is described as a design rationale in peptide drug development [2]. Neither source establishes that improved stability translates into a clinical outcome.

Comparison of reported observations

If you are reading this for personal health reasons

The materials described on this page are sold for laboratory research use only, and we do not provide dosing, administration or medical guidance of any kind. Nothing here is a recommendation to obtain or use any compound. Anyone considering a peptide or related compound for themselves should speak to a licensed clinician.

Sources

• [1] Building Blocks of 2,3-Diaminopropionic Acid Functionalized with an Oxa-Acid Spacer Shift the Functional Profile of Human Cathelicidin LL-37: Enhanced Enzymatic Stability and Selective Suppression of Neutrophil Degranulation. https://pubmed.ncbi.nlm.nih.gov/42653651/
• [2] FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective. https://pubmed.ncbi.nlm.nih.gov/42041173/
• [3] Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS). https://europepmc.org/article/PMC/PMC12357219